<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04205552</url>
  </required_header>
  <id_info>
    <org_study_id>CA224-063</org_study_id>
    <nct_id>NCT04205552</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients</brief_title>
  <acronym>NEOpredict</acronym>
  <official_title>Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the feasibility of four weeks of
      preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with
      early stage or locally advanced non-small cell lung cancer eligible for curative resection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab</measure>
    <time_frame>Within 43 days after first study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimation of pathological tumor response rate</measure>
    <time_frame>Within 43 days after first study medication (day of surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of curative (R0) resection rate</measure>
    <time_frame>Within 43 days after first study medication (day of surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival rate at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of disease-free survival rate at 12 months per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiologic response</measure>
    <time_frame>After 3, 6, 9 and 12 months post-surgery</time_frame>
    <description>radiologic response on computed tomography per Response evaluation criteria in solid tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>within 90 days after surgery</time_frame>
    <description>Estimation of morbidity within 90 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>within 90 days after surgery</time_frame>
    <description>Estimation of mortality within 90 days after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>NSCLC Stage II</condition>
  <condition>NSCLC, Stage IIIA</condition>
  <condition>NSCLC, Stage I</condition>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 2 cycles, every two weeks (q2w)
o Nivolumab 240 mg i.v. over 30 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab/Relatlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab/Relatlimab 2 cycles, every two weeks (q2w)
Nivolumab 240 mg i.v. over 30 min
Relatlimab 80 mg i.v. over 30 min (within 30 min of nivolumab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab 10 MG/ML Intravenous Solution</intervention_name>
    <description>Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min</description>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_label>Nivolumab/Relatlimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relatlimab 10 MG/ML Intravenous Solution</intervention_name>
    <description>Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min</description>
    <arm_group_label>Nivolumab/Relatlimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed non-small cell lung cancer (NSCLC) eligible for
             anatomic resection (Clinical stages I B, II and selected stage III A)

          -  Eastern Cooperative Oncology Group (ECOG) ≤ 1

          -  Sufficient pulmonary function to undergo curative lung cancer surgery

          -  Adequate hematological, hepatic and renal function parameters:

          -  Sufficient cardiac left ventricular defined as left ventricular ejection fraction
             (LVEF) ≥ 50% documented either by echocardiography or multigated acquisition scan
             (MUGA)

          -  Patient able and willing to provide written informed consent and to comply with the
             study protocol and with the planned surgical procedures

        Exclusion Criteria:

          -  Active or history of autoimmune disease or immune deficiency

          -  Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14
             days of study drug administration.

          -  Subjects who have undergone organ transplant or allogeneic stem cell transplantation.

          -  Uncontrolled or significant cardiovascular disease

          -  Patients with active neurological disease

          -  Active malignancy or a prior malignancy within the past 3 years.

          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of study
             medication

          -  Peripheral polyneuropathy NCI CTCAE Grade ≥ 2

          -  History of gastric perforation or fistulae in past 6 months

          -  Serious or non-healing wound, ulcer, or bone fracture within 28 days prior to
             enrollment.

          -  The patient has undergone major surgery within 28 days prior to enrollment except
             staging mediastinoscopy, diagnostic Video Assisted Thoracoscopic Surgery (VATS) or
             implantation of a venous port-system.

          -  Any other concurrent preoperative antineoplastic treatment including irradiation

          -  Pregnant/Breastfeeding women

          -  Subjects with history of severe toxicity or life-threatening toxicity (grade 3 or 4)
             related to prior immune therapy

          -  Prior treatment with Lymphocyte-activation gene 3 (LAG-3) targeting Agent

          -  Previous treatment with Nivolumab or Relatlimab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schuler, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katrin Appel, PhD</last_name>
    <phone>0049 201 723 77411</phone>
    <email>katrin.appel@uk-essen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jessa Hospital Hasselt</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

